GLEN ALLEN, Va., Sept. 20, 2011 /PRNewswire/ -- Rock Creek Pharmaceuticals, a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), announced that on September 19, 2011 a utility patent application was filed with the Patent and Trademark Office ("PTO"). This utility patent application is based on several previously-filed provisional applications, and it is directed to various products containing anatabine and the administration of anatabine to reduce inflammation. Anatabine has the potential to be particularly useful for nutritional support for disorders involving inflammation that is associated with Nuclear Factor-KappaB (NF-kB) mediated transcription. NF-kB is a transcription factor that operates in cells and participates in the immune response. NF-kB mediated transcription is associated with numerous disorders, including those with inflammatory components, abnormal immune response and/or inappropriate cell proliferation. NF-kB is associated with over 200 inflammatory pathways.
Rock Creek Pharmaceuticals has developed a dietary supplement, Anatabloc™, that contains anatabine citrate as well as Vitamins A & D3, which was launched on August 30. This is the second dietary supplement developed by the company: CigRx®, the first product, was introduced in August, 2010. CigRx® is a non-nicotine, non-tobacco alternative for smokers that reduces the urge to light a cigarette, and it contains both anatabine citrate and yerba mate. It is believed that this combination of dietary ingredients mimics the brain activity that occurs when nicotine is inhaled. It is available for purchase via a dedicated product website (www.cigrx.com) or the Amazon.com purchase portal. CigRx also is available at all CVS-Pharmacy stores in the Richmond, VA area, and in roughly 500 independent retail and convenience stores throughout New England.
Anatabloc™ was launched on August 30, and it is targeted to provide anti-inflammatory support. Like CigRx®, Anatabloc™ is being sold through a dedicated product website (www.anatabloc.com) and via the Amazon.com purchase portal. The company anticipates that international shipping will be available as well for Anatabloc™ within the next two weeks.
The Anatabloc™ website also includes a section that can be accessed by physicians and other licensed health care providers who want to learn about the research related to anatabine. The company also is hosting a series of oral presentations by researchers who have been exploring anatabine, for physicians and allied providers. Anatabloc™ also will be marketed directly to physicians and health care providers by sales representatives who have experience in outreach to these individuals.
Paul L. Perito, Rock Creek's Chairman and CEO stated, "While the Anatabloc™ introduction has been underway for less than 30 days, we have been very pleased with the brisk sales volume."
Certain statements in this press release other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "continues," "likely," "may," "opportunity," "potential," "projects," "will," "expects," "plans," "intends" and similar expressions to identify forward-looking statements, whether in the negative or the affirmative. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties, factors and contingencies include, without limitation, the challenges inherent in new product development initiatives through Star Tobacco and Rock Creek, the uncertainties inherent in the progress of scientific research, our ability to raise additional capital in the future that is necessary to maintain our business, potential disputes concerning our intellectual property, risks associated with litigation regarding such intellectual property, uncertainties associated with the development, testing and regulatory approvals of our low-TSNA tobacco, related tobacco products and pharmaceutical and nutraceutical products , market acceptance of our new smokeless tobacco products and nutraceutical and pharmaceutical products, competition from companies with greater resources than us, our dependence on key employees and on our prior strategic relationships with Brown & Williamson Tobacco Corporation in light of its combination with R.J. Reynolds Tobacco Company, Inc.
Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that the expectations will be attained or that any deviation will not be material. See additional discussion under "Risk Factors" in the Company's Annual Report on Form 10-K as filed with the SEC on March 16, 2011, and other factors detailed from time to time in the Company's other filings with the SEC, available at www.sec.gov. All information in this release is current as of this date, and the Company undertakes no obligation to update or advise upon any such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
About Star Scientific
Star Scientific is a technology-oriented company with a mission to reduce the harm associated with tobacco at every level. It is engaged in the development of dissolvable smokeless tobacco products that deliver fewer carcinogenic toxins, principally through the utilization of the innovative StarCured® tobacco curing technology. Its subsidiary, Rock Creek Pharmaceuticals, Inc., is involved in the development of nutraceuticals as well as products to address neurological and mood disorders. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, D.C. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, an Executive, Scientific & Regulatory Affairs office in Bethesda, MD, and a manufacturing facility in Chase City, VA.
See Star's website at: http://www.starscientific.com
Sara Troy Machir
Vice President, Communications & Investor Relations
SOURCE Star Scientific, Inc.